The access and use of GLP-1 receptor agonists in people with eating disorders in the UK: A mixed method study

Le résumé fourni par la source

Objective: To explore the use, access, and motivations of individuals with eating disorders (EDs) attempting to access Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight management in the UK. Method: A mixed-methods convergent parallel design was used. Eligible participants were aged 16+, had an ED, and had attempted to access GLP-1 RAs in the past two years. Seventy-two participants completed an online survey, with quantitative data analysed descriptively and qualitative data analysed thematically. Results: Ninety three percent (n=67) reported current or previous GLP-1 RA’s use and most common motivations were weight loss and binge eating reduction. The most frequent prescriber was online pharmacies (n=52, 74.3%). When prescribed, two thirds were asked about an ED but did not disclose this, one quarter were not asked about EDs. Thirty seven percent (n=25) of participants who received medication did not meet BMI prescription requirements and the approximately half did not receive ongoing monitoring. Qualitative themes found that motivations for using GLP-1 RAs were guided by ED cognitions and recovery, and uncertainty emerged surrounding intentions of long-term use. Conclusion: Despite screening of ED’s and BMI being recommended, most participants in this study obtained GLP-1 RAs for weight loss with little ongoing monitoring, suggesting the need for more robust regulation.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.